Advertisement

Picture Mologen AG Investing in Power of Immunotherapy Middle 600x60px
Document › Details

Clavis Pharma ASA. (1/18/12). "Press Release: Clavis Pharma. Raises NOK 163 Million in Private Placement". Oslo.

Organisations Organisation Clavis Pharma ASA
  Today Aqualis ASA
  Group Aqualis ASA
  Organisation 2 Braganza AS
Products Product elacytarabine
  Product 2 CP-4126 (CO-101)
Index term Index term Clavis Pharma–SEVERAL: investment, 201201 private placement NOK163m 2.86m new shares NOK53/share
Persons Person Hellebø, Olav (ReNeuron 201507 CEO before Clavis Pharma 201108 CEO)
  Person 2 Manum, Gunnar (Clavis Pharma 201107 CFO)
     


   
Record changed: 2015-08-10

Advertisement

Picture BIO Deutschland EBDC 2016 Frankfurt 600x60px

More documents for Aqualis ASA


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO Europe 2016 BEU Cologne November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Mologen AG Investing in Power of Immunotherapy Middle 120x180px Picture EuropaBio European Biotech Week 2016 September 120x180px Picture BIO Deutschland EBDC 2016 Frankfurt 120x240px Picture EBD Group BIO Europe 2016 BEU Cologne November 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px